RESUMO
Androgenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80% Caucasian men and 42% of women. Patients afflicted with androgenetic alopecia may undergo significant impairment of quality of life. The European Dermatology Forum (EDF) initiated a project to develop evidence-based guidelines for the treatment of androgenetic alopecia. Based on a systematic literature research the efficacy of the currently available therapeutic options was assessed and therapeutic recommendations were passed in a consensus conference. The purpose of the guideline is to provide dermatologists with an evidence-based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia.
Assuntos
Alopecia/terapia , Medicina Baseada em Evidências , Inibidores de 5-alfa Redutase/uso terapêutico , Quimioterapia Combinada , Dutasterida/uso terapêutico , Feminino , Finasterida/uso terapêutico , Cabelo/transplante , Humanos , Terapia com Luz de Baixa Intensidade , Masculino , Minoxidil/uso terapêutico , Avaliação de Resultados em Cuidados de Saúde , Plasma Rico em Plaquetas , Guias de Prática Clínica como Assunto , Vasodilatadores/uso terapêuticoRESUMO
Androgenetic alopecia (AGA) is the most common hair loss disorder, affecting both men and women. Due to the frequency and the often significant impairment of life perceived by the affected patients, competent advice, diagnosis and treatment is particularly important. As evidence-based guidelines on hair disorders are rare, a European consensus group was constituted to develop guidelines for the diagnostic evaluation and treatment of AGA. This S1 guideline for diagnostic evaluation of AGA in men, women and adolescents reviews the definition of AGA and presents expert opinion-based recommendations for sex-dependent steps in the diagnostic procedure.
Assuntos
Alopecia/diagnóstico , Adolescente , Adulto , Alopecia/classificação , Alopecia/epidemiologia , Biópsia , Medicina Baseada em Evidências , Feminino , Humanos , Masculino , Prevalência , Fatores SexuaisRESUMO
Acrodermatitis chronica atrophicans (ACA) represents the persistent late stage of borreliosis in which Borrelia species may survive for decades. Occasionally, B-cell lymphoma may develop in these patients, and additional neoplastic complications such as basal cell carcinoma or squamous cell carcinoma (SCC) have been reported once each over the past 60 years. Here we describe, to the best of our knowledge, the first case of metastatic SCC in a European patient with long-standing ACA caused by Borrelia burgdorferi sensu stricto. Our case highlights a potential pathophysiological connection of untreated Borrelia infection with the initiation or progression of SCC and should alert dermatologists to this rare complication.
